{"id":1025,"date":"2002-07-01T12:03:00","date_gmt":"2002-07-01T10:03:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2002\/wachstumsfaktoren-bei-peripherer-arterieller-verschlusskrankheit"},"modified":"2002-07-01T12:03:00","modified_gmt":"2002-07-01T10:03:00","slug":"wachstumsfaktoren-bei-peripherer-arterieller-verschlusskrankheit","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2002\/wachstumsfaktoren-bei-peripherer-arterieller-verschlusskrankheit","title":{"rendered":"Wachstumsfaktoren bei peripherer arterieller Verschlu\u00dfkrankheit"},"content":{"rendered":"<p>Eine randomisierte plazebokontrollierte Phase-II-Studie mit dem Akronym TRAFFIC (TheRapeutic Angiogenesis with recombinant Fibroblast growth Factor-2 for Intermittent Claudication) hat den Nutzen und die Sicherheit von Gef\u00e4\u00df-Wachstumsfaktoren bei peripherer arterieller Verschlu\u00dfkrankheit (pAVK) untersucht (Lederman, R.J., et al.: Lancet 2002, 359, 2053; s.a. AMB 1998, 32, 61.). In diese Multicenterstudie wurden insgesamt 190 Patienten mit pAVK (im [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eine randomisierte plazebokontrollierte Phase-II-Studie mit dem Akronym TRAFFIC (TheRapeutic Angiogenesis with recombinant Fibroblast growth Factor-2 for Intermittent Claudication) hat den Nutzen und die Sicherheit von Gef\u00e4\u00df-Wachstumsfaktoren bei peripherer arterieller Verschlu\u00dfkrankheit (pAVK) untersucht (Lederman, R.J., et al.: Lancet 2002, 359, 2053; s.a. AMB 1998, 32, 61.). In diese Multicenterstudie wurden insgesamt 190 Patienten mit pAVK (im [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[229,2542,2543,2541,230,2601],"class_list":["post-1025","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-claudicatio-intermittens","tag-fgf","tag-fibroblast-growth-factor","tag-fibroblasten-wachstumsfaktor","tag-periphere-arterielle-verschlusskrankheit","tag-traffic-studie"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1025","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1025"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1025\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1025"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1025"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1025"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}